Maxscend Microelectronics Company Limited (SHE:300782)

Verve Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	4,047	4,480	4,375	3,675	4,633	2,792
Other Revenue	6.51	6.51	3.32	2.18	0.18	-
Revenue	4,053	4,487	4,378	3,677	4,634	2,792
Revenue Growth (YoY)	-16.54%	2.48%	19.05%	-20.63%	65.95%	84.62%
Cost of Revenue	2,721	2,880	2,441	2,041	2,023	1,364
Gross Profit	1,332	1,607	1,938	1,637	2,611	1,428
Selling, General & Admin	232.97	237.41	201.12	139.16	97.46	59.65
Research & Development	905.84	997.07	628.94	449.28	304.25	182.29
Other Operating Expenses	-4.92	6.34	10.2	5.89	3.3	3.89
Operating Expenses	1,135	1,244	846.17	583.78	417.76	244.55
Operating Income	196.85	362.78	1,091	1,053	2,193	1,184
Interest Expense	-53.05	-37.12	-2.34	-0.55	-0.17	-
Interest & Investment Income	24.71	18.68	53.28	13.82	34.76	9.62
Currency Exchange Gain (Loss)	-0.95	-0.95	0.76	23.15	-23.4	-22.95
Other Non Operating Income (Expenses)	5.25	-0.79	1.02	-3.33	-3.32	-0.58
EBT Excluding Unusual Items	172.81	342.6	1,144	1,086	2,201	1,170
Gain (Loss) on Sale of Investments	-1.39	-1.32	18.81	-1.64	8.74	36.84
Gain (Loss) on Sale of Assets	3.5	6.77	1.1	0.02	0	-
Asset Writedown	-54.68	-	-	-	-0	-0.04
Other Unusual Items	33.34	33.43	6.88	4.99	205.17	10.43
Pretax Income	153.59	381.48	1,171	1,089	2,415	1,217
Income Tax Expense	-5.18	-21.16	51.51	10.81	280.27	146.65
Earnings From Continuing Operations	158.77	402.65	1,119	1,078	2,135	1,071
Minority Interest in Earnings	-1.33	-0.82	2.88	-9.14	0.13	2.29
Net Income	157.43	401.83	1,122	1,069	2,135	1,073
Net Income to Common	157.43	401.83	1,122	1,069	2,135	1,073
Net Income Growth	-86.92%	-64.20%	4.96%	-49.91%	99.00%	115.78%
Shares Outstanding (Basic)	534	534	534	534	532	518
Shares Outstanding (Diluted)	535	535	535	534	533	518
Shares Change (YoY)	-0.08%	-0.04%	0.18%	0.23%	2.73%	14.28%
EPS (Basic)	0.29	0.75	2.10	2.00	4.01	2.07
EPS (Diluted)	0.29	0.75	2.10	2.00	4.01	2.07
EPS Growth	-86.91%	-64.19%	4.77%	-50.02%	93.71%	88.81%
Free Cash Flow	-1,407	-1,788	-227.66	-768.48	-1,709	852.01
Free Cash Flow Per Share	-2.63	-3.35	-0.43	-1.44	-3.21	1.64
Dividend Per Share	0.102	0.102	0.224	0.170	0.438	0.347
Dividend Growth	-54.46%	-54.46%	31.77%	-61.14%	26.01%	-10.01%
Gross Margin	32.86%	35.80%	44.26%	44.50%	56.35%	51.16%
Operating Margin	4.86%	8.09%	24.93%	28.63%	47.33%	42.40%
Profit Margin	3.88%	8.96%	25.64%	29.08%	46.07%	38.42%
Free Cash Flow Margin	-34.72%	-39.85%	-5.20%	-20.90%	-36.87%	30.51%
EBITDA	841.52	920.8	1,303	1,148	2,241	1,213
EBITDA Margin	20.76%	20.52%	29.76%	31.21%	48.36%	43.45%
D&A For EBITDA	644.67	558.02	211.4	95.04	47.57	29.29
EBIT	196.85	362.78	1,091	1,053	2,193	1,184
EBIT Margin	4.86%	8.09%	24.93%	28.63%	47.33%	42.40%
Effective Tax Rate	-	-	4.40%	0.99%	11.61%	12.05%
Revenue as Reported	4,053	4,487	4,378	3,677	4,634	2,792

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.